Journal
New England Journal of Medicine
Publication Date
2-13-2025
Volume
392
Issue
7
First Page
653
Last Page
665
Document Type
Open Access Publication
DOI
10.1056/NEJMoa2403991
Rights and Permissions
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13;392(7):653-665. doi: 10.1056/NEJMoa2403991. Copyright © 2024 Massachusetts Medical Society. Reprinted with permission.
Recommended Citation
Chan, Jennifer A; Trikalinos, Nikolaos A; and et al., "Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors." New England Journal of Medicine. 392, 7. 653 - 665. (2025).
https://digitalcommons.wustl.edu/oa_4/4912
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
